Quietly, carefully, delicately, University officials this summer began exploring the possibilities of setting up or investing in a company that would develop and patent biomedical procedures and substances created in Harvard's laboratories.
Spurred on by visions of potentially huge financial rewards, and by the work of Mark S. Ptashne, professor of Biochemistry and Molecular Biology, whose lab is doing pioneering recombinant DNA research with much-heralded interferon, discussions began.
But they were only preliminary, and the concept--sure to rankle faculty members who have either gone to the trouble of establishing their own companies or may question Harvard's involvement in business--will undoubtedly take much time to evolve.
Details were scarce, but sources close to the talks said the University--which owns patent rights on professor's biomedical discoveries--was considering creating a middle-man company which would develop the product or technique.
Some officials said that despite the many dilemmas involved, the concept was a potential winner, providing professors a channel for inventions and the University a way to make money on the space that it "rents" to its Faculty.
Other sources, however, warned that the issue was far too controversial; when the topic reaches the Faculty for debate, they predicted, more than just a few eyebrows would be raised.
Read more in News
HCUA Clashes on Open Elections, Will Vote on Question Next WeekRecommended Articles
-
Medical School to Build $300M Research FacilityIn order to meet increasing demands for research facilities, Harvard Medical School is planning to construct a $250 to $300
-
Students Rally for AudobonStudents rallied at Columbia University on Monday and blocked access to classrooms and offices to save the building in which
-
MIT Faculty Debates Proposed FacilityMIT faculty members this week expressed concern that a proposed multimillion-dollar biomedical research facility affiliated with the school might lead
-
New Reagan Budget Proposals May Raise Research FundingHarvard could see a surprising increase in federal research funding for nearly all sciences next year under President Reagan's proposed
-
Capitalists Dream of GenesAfter the initial burst of public fascination that accompanies most new ventures into high technology, the recombinant DNA industry has
-
SEAS Concentration Gains PopularityThe School of Engineering and Applied Sciences is growing yet again—with 220 new sophomores, SEAS saw a 62 percent increase in total concentrators this week, according to tentative data provided by the school.